Relationship between the clinical effects of berberine on severe congestive heart failure and its concentration in plasma studied by HPLC

Area of Science:

• Pharmacology and Cardiology
• Clinical Trial Analysis

Background:

• Berberine is recognized for its potential in managing ventricular premature beats (VPBs) and improving outcomes in congestive heart failure (CHF).
• Optimizing berberine's therapeutic efficacy and minimizing side effects necessitates understanding its relationship with plasma concentration in CHF patients.

Purpose of the Study:

• To investigate the correlation between plasma berberine concentration and its therapeutic effects on VPBs and left ventricular ejection fraction (LVEF) in patients with CHF.
• To establish a potential therapeutic range for berberine in CHF management.

Main Methods:

• Patients with CHF received 1.2 g/day oral berberine after initial assessment of VPBs and LVEF.
• Plasma berberine concentrations were quantified using High-Performance Liquid Chromatography (HPLC) with chloroform extraction.
• Dynamic electrocardiogram (DCG) and LVEF were reassessed after two weeks of berberine therapy.

Main Results:

• A statistically significant decrease in VPB frequency and complexity, along with an increase in LVEF, was observed in patients with plasma berberine levels exceeding 0.11 mg/L.
• These improvements were more pronounced (p < 0.01) in patients with higher berberine concentrations compared to those with lower concentrations (p < 0.05).
• The HPLC method demonstrated high recovery (96.5%), a wide linear range (40-1600 ng/mL), and a low detection limit (0.4 ng).

Conclusions:

• Plasma berberine concentration is a critical factor influencing its therapeutic effectiveness in managing VPBs and improving cardiac function in CHF patients.
• Achieving plasma berberine concentrations above 0.11 mg/L appears to be associated with superior clinical benefits for patients with congestive heart failure.